After winning a seven-year patent battle, Regeneron Pharmaceuticals, Inc. is once again in litigation with Amgen, Inc. over the PCSK9 inhibitor market. This time around, Regeneron claims Amgen is engaging in an anticompetitive rebate “bundling scheme” to keep its cholesterol-lowering drug Praluent (alirocumab) off third-party payor formularies.
In a 27 May complaint, Regeneron contends that Amgen is bundling sales of its competing PCSK9 inhibitor Repatha (evolocumab)...





